Voraxaze (Megludase/Glucarpidaseor) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Voraxaze (Megludase/Glucarpidaseor) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Voraxaze or Megludase Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.

The Voraxaze (megludase) market is experiencing significant growth, largely due to a refined understanding of methotrexate toxicity management and the increased adoption of high-dose chemotherapy. The historic rise can be attributed to the availability of recombinant enzyme antidotes and enhanced renal toxicity clinical awareness. Moving forward, emphasis on precision oncology supportive care, increasing investments in emergency oncology therapeutics, and expanding oncology infrastructure are expected to further drive market growth.

An increase in targeted enzyme detoxification therapies and clinical focus on chemotherapy toxicity management are notable future trends. Healthcare providers are leaning towards rapid-response detoxification treatments and innovative enzyme-based antidotes, which are becoming integral to hospital-based acute care protocols.

The rising prevalence of cancer is a key driver for the Voraxaze market. With an aging population, changes in lifestyle, environmental exposures, and improved detection methods, cancer rates are on the rise. Voraxaze plays a vital role in treating high methotrexate toxicity, reducing severe chemotherapy side effects. For instance, the American Cancer Society projects an increase in cancer cases in the United States from 1,958,310 in 2023 to 2,001,140 in 2024, reflecting a 2.19% rise.

The expansion of oncology care centers, which diagnose, treat, and manage cancer, supports the growth of the Voraxaze market. These centers improve access to methotrexate toxicity treatment. As of 2023, there were 72 National Cancer Institute-Designated Cancer Centers in the US, indicating a growth in accessible treatment facilities.

Clinical trials are pivotal in propelling the Voraxaze market by demonstrating the safety and efficacy of Voraxaze in managing methotrexate toxicity. The National Institutes of Health reported a 9.5% increase in registered clinical trials in the USA from 2022 to 2023. These trials aid regulatory approvals and encourage the drug's adoption in medical practice.

BTG Specialty Pharmaceuticals and SERB Pharmaceuticals are key players in the Voraxaze market. North America is the largest regional market, with Asia-Pacific, Europe, and other regions also contributing significantly. Tariffs are impacting the market by raising costs for imported materials and logistics. This challenge is pushing for domestic enzyme production and regional manufacturing partnerships to improve supply chain security.

The Voraxaze market research report provides extensive insights into market size, regional shares, competitors, market segments, trends, and opportunities. It offers an in-depth analysis of the current and future industry landscape, providing a comprehensive view of the market dynamics.

Voraxaze, also known as Megludase or Glucarpidase, is a recombinant enzyme crucial for treating patients with delayed methotrexate clearance due to kidney dysfunction. It converts methotrexate into inactive metabolites, thus playing a critical role in managing severe toxicity and preventing complications. Its primary indications include toxic plasma methotrexate and acute renal failure, with distribution through hospitals and pharmacies for various patient demographics.

The Voraxaze market encompasses sales of glucarpidase enzyme products and supportive care products, with values defined as 'factory gate' values representing revenues from goods sold by manufacturers, indicating both the direct sales and supportive services provided.

Key Topics Covered:

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Voraxaze or Megludase Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Voraxaze or Megludase Market Attractiveness Scoring and Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment and Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Voraxaze or Megludase Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List of Key Raw Materials, Resources & Suppliers

3.3. List of Major Distributors and Channel Partners

3.4. List of Major End Users

4. Global Voraxaze or Megludase Market Trends and Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics and Precision Medicine

4.1.2 Digitalization, Cloud, Big Data and Cybersecurity

4.1.3 Industry 4.0 and Intelligent Manufacturing

4.1.4 Artificial Intelligence and Autonomous Intelligence

4.1.5 Sustainability, Climate Tech and Circular Economy

4.2. Major Trends

4.2.1 Increasing Use of Targeted Enzyme Detoxification Therapies

4.2.2 Growing Clinical Focus on Chemotherapy Toxicity Management

4.2.3 Rising Adoption of Emergency Oncology Support Drugs

4.2.4 Expansion of Precision Supportive Care Treatments

4.2.5 Strengthening Hospital-Based Acute Care Protocols

5. Voraxaze or Megludase Market Analysis of End Use Industries

5.1 Adult Patients

5.2 Pediatric Patients

5.3 Geriatric Patients

5.4 Oncology Hospitals

5.5 Emergency Care Centers

6. Voraxaze or Megludase Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, and Covid and Recovery on the Market

7. Global Voraxaze or Megludase Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis

7.1. Global Voraxaze or Megludase PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Voraxaze or Megludase Market Size, Comparisons and Growth Rate Analysis

7.3. Global Voraxaze or Megludase Historic Market Size and Growth, 2020-2025, Value ($ Billion)

7.4. Global Voraxaze or Megludase Forecast Market Size and Growth, 2025-2030, 2035F, Value ($ Billion)

8. Global Voraxaze or Megludase Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Voraxaze or Megludase Market Segmentation

9.1. Global Voraxaze or Megludase Market, Segmentation by Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Toxic Plasma Methotrexate, Acute Renal Failure, Chemotherapy Toxicity

9.2. Global Voraxaze or Megludase Market, Segmentation by Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

9.3. Global Voraxaze or Megludase Market, Segmentation by End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Adult, Pediatric, Geriatric

For more information about this report visit https://www.researchandmarkets.com/r/rlum8q

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.